NOTIFICATION

The following notification is being circulated in accordance with Article 10.4.

1. Party to Agreement notifying: UNITED STATES


3. Notified under Article 2.5.2 [X], 2.6.1 [], 7.3.2 [], 7.4.1 [], other:

4. Products covered (HS or CCCN where applicable, otherwise national tariff heading):

   Products containing Lidocaine or Dibucaine

5. Title: Requirements for Child-Resistant Packaging; Proposed Requirements for Products Containing Lidocaine or Dibucaine (8 pages)

6. Description of content: The Commission is proposing to require child-resistant packaging for products containing (1) more than 5.0 milligrams (mg.) of Lidocaine in a single package or (2) more than 0.5 mg. of Dibucaine in a single package. Lidocaine and Dibucaine are used in prescription drugs and over-the-counter drug products that are applied to the skin or mucous membranes to provide an anaesthetic effect.

7. Objective and rationale: To protect children under five years of age from serious personal injury and serious illness resulting from ingesting such substances.


9. Proposed date of adoption and entry into force: To be determined

10. Final date for comments: 19 October 1992

11. Texts available from: National enquiry point [X] or address of other body:

92-1179